A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer

CompletedOBSERVATIONAL
Enrollment

308

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

December 27, 2019

Study Completion Date

December 27, 2019

Conditions
Localized or Locally Advanced Prostate Cancer
Trial Locations (25)

100034

Research Site, Beijing

100191

Research Site, Beijing

150081

Research Site, Harbin

200032

Research Site, Shanghai

200433

Research Site, Shanghai

210009

Research Site, Nanjing

210029

Research Site, Nanjing

250012

Research Site, Jinan

250021

Research Site, Jinan

264000

Research Site, Yantai

310022

Research Site, Hangzhou

315000

Research Site, Ningbo

430022

Research Site, Wuhan

430060

Research Site, Wuhan

510120

Research Site, Guangzhou

510530

Research Site, Guangzhou

519000

Research Site, Zhuhai

528000

Research Site, Foshan

610072

Research Site, Chengdu

830054

Research Site, Ürümqi

Unknown

Research Site, Guangdong

Research Site, Langfang

Research Site, Shijiazhuang

Research Site, Xi'an

CN-430030

Research Site, Wuhan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY